Biotech Values

[genisi]

Is it safe to assume that AZN/RIGL incorporated a radiographic study into the ongoing pivotal fostamatinib trials?

Yes, see the 2nd primary outcome endpoint in the phase III trial:

Proportion of patients with ACR20 compared to placebo (ACR20 = American College of Rheumatology 20% response criteria) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Change from baseline to week 24 in mTSS (mTSS = radiographic modified total Sharp score) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

http://clinicaltrials.gov/ct2/show/NCT01197521